Lumito AB (NGM:LUMITO) Marketable Securities: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:LUMITO Lumito AB NGM:LUMITO
18 GF Score
Price kr1.50
! 2 Warning Signs
View Full Analysis

What is Lumito AB Marketable Securities?

Lumito AB NGM:LUMITO -5.66% 18 Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Lumito AB's Marketable Securities for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Lumito AB  (NGM:LUMITO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Lumito AB Marketable Securities Related Terms

Lumito AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Lumito AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumito AB Marketable Securities Chart

Lumito AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lumito AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:LUMITO
18GF Score
Lumito AB NGM:LUMITO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumito AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.00 Mil mean?
Lumito AB (NGM:LUMITO) has a Marketable Securities of kr0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lumito AB and its competitors.
Is Lumito AB's Marketable Securities too high?
Lumito AB's current Marketable Securities is kr0.00 Mil. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's Marketable Securities compare to TMO and DHR?
Lumito AB's Marketable Securities of kr0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lumito AB and its competitors. Lumito AB's current Marketable Securities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current Marketable Securities of kr0.00 Mil. The current Marketable Securities is kr0.00 Mil. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumito AB Business Description

Address Scheelevagen 19, Lund, SWE, 223 63
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score

Get the complete analysis for NGM:LUMITO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.50
Price